$HOWL

$0.98 +$0.00 (0.05%) Close

$HOWL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 48.6M shares outstanding

Who owns HOWL?

By type of holder

Institutions 22.4% Insiders 72.8% Everyone else 4.9%

Concentration Top 10 holders own 31.2%

Ra Capital Management, L.P. 4.9% · Rajeev Shah 4.1%

Institutional ownership

22.4%

-6.5 pts vs last qtr

Institutional holders

-3 vs last qtr

Net shares bought

−3.1M

by institutions in Q2 2026

New / sold out

9 / 12

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Balyasny Asset Management L.P. NEW +1.8M
Verdad Advisers, LP +318.9K

Biggest sellers in Q2 2026

Ra Capital Management, L.P. −4.3M
MPM Bioimpact LLC −1.1M

Who is planning to sell?

Notices of proposed sale, last 12 months

$4.41M

102 notices from 6 people

Shares covered

6.1M

12.54% of the company

Arranged in advance

100%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

MPM BioVentures 2014, L.P. Shareholder 10b5-1 $1.91M
UBS Oncology Impact Fund, L.P. Shareholder 10b5-1 $1.58M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+4557.7%

+115.59% a year

Each share's claim on the business

−97.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $35.2M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years58% 3–5 years7% 1–3 years3% Under 1 year32%

Quarterly turnover

34.0%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting HOWL on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Ra Capital Management, L.P. 13D · 4.1%	2.4M	4.91%	−4.3M (−64.3%)	≤2021	0.0%
Shares held by quarter Peak holding6.7M (Q2'25) Change over 8 quarters−3.8M Share of the company4.910% Disclosed stake13D · 4.1% Ra Capital Management, L.P.'s full portfolio →
BA Balyasny Asset Management L.P.	1.8M	3.68%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding1.8M (Q2'26) Change over 8 quarters+1.8M Share of the company3.680% Balyasny Asset Management L.P.'s full portfolio →

Ra Capital Management, L.P.

13D · 4.1%

2.4M

% of company

4.91%

Change vs last qtr

−4.3M (−64.3%)

Held since

≤2021

Balyasny Asset Management L.P.

1.8M

% of company

3.68%

Change vs last qtr

NEW

Held since

Q2 '26

28 more super investors behind a free account

See every manager holding Werewolf Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting HOWL on Form N-PORT; together they hold 3.3% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$314K	873.7K	1.80%	0.00%	June 30, 2026
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$192K	204.0K	0.42%	0.00%	August 31, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$314K

% of company

1.80%

% of the fund

0.00%

As of

June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$192K

% of company

0.42%

% of the fund

0.00%

As of

August 31, 2026

6 more funds behind a free account

See every fund holding Werewolf Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RS Rajeev Shah 5%+ holder 13D · 4.1%	2.0M	4.09%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company4.090% Disclosed stake13D · 4.1% View the 13D/G filing →
PK Peter Kolchinsky 5%+ holder 13D · 4.1%	2.0M	4.09%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company4.090% Disclosed stake13D · 4.1% View the 13D/G filing →

Rajeev Shah

5%+ holder13D · 4.1%

2.0M

% of company

4.09%

Change vs last qtr

—

Held since

—

Peter Kolchinsky

5%+ holder13D · 4.1%

2.0M

% of company

4.09%

Change vs last qtr

—

Held since

—

15 more holders behind a free account

See every insider and 5%+ holder of Werewolf Therapeutics Inc.

Comments